Qiagen N.V. operates in the Biological products exc. diagnostic sector. QIAGEN N.V. is a holding company, which provides technologies and products for preanalytical sample preparation and linked molecular assay solutions. The Company has developed a portfolio of more than 500 consumable products and automated solutions for sample collection, and nucleic acid and protein handling, separation, and purification, as well as open and target-specific assays. The Company also supplies diagnostic kits, tests, and assays for human and veterinary molecular diagnostics. Products are sold to academic research markets, to pharmaceutical and biotechnology companies, to applied testing customers, as well as to molecular diagnostics laboratories. In September 2009, it acquired DxS Ltd. In December 2009, the Company acquired SABiosciences Corporation. In January 2010, the Company acquired ESE GmbH. In January 2011, the Company announced the formation of its India subsidiary, QIAGEN India Pvt. Ltd. In August 2011, the Company acquired Cellestis Limited. In our complete report available for purchase the company is compared to: Spyker Cars N.V., Zaklady Azotowe W Tarnowie Moscicach SA and Accell Group NV.